First Manhattan sues Vivus for delaying shareholder meet
July 16 (Reuters) - Obesity drug maker Vivus Inc's proxy battle with its top investor intensified on Tuesday with First Manhattan Co (FMC) filing a lawsuit alleging that Vivus's directors illegally delayed the company's shareholder meeting to keep themselves in office.
FMC holds nearly 9.9 percent of Vivus and has been critical of the company for mishandling the launch and marketing of diet pill Qsymia.
Vivus decided to postpone its shareholder meeting to July 18 from July 15 on Monday, saying FMC's advisers had made false statements to shareholders.
- Malaysia jet sent 'pings' after going missing, sources say |
- Russia holds war games near Ukraine; Merkel warns of catastrophe |
- Rescuers search site of NY building collapse; seven dead |
- White House tried to mediate dispute between Senate, CIA panel: source
- Missing jet may have strayed to west, Malaysia military says |